| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 83
Poster Abstracts Antiretroviral Agents in Resource Limited Settings Wednesday, 1:30 - 3:30 pm Poster Hall |
| 580 | Protease and Reverse Transcriptase Polymorphisms in Treatment-naďve Individuals Infected with HIV-1 Subtype C in Southern Africa O K'Aluoch*1, R Donovan1, E Liu1, C Gray2, C Williamson3, and H Sheppard1 1California Dept. of Hlth. Svcs., Richmond, USA; 2Natl. Inst. for Communicable Diseases, Johannesburg, South Africa; and 3Univ. of Cape Town, South Africa |
| 581 | Antiretroviral Drug Content in Products from Developing Countries S Penzak*1, E Acosta2, M Turner2, J Tavel3, and H Masur1 1Clin. Ctr., NIH, DHHS, Bethesda, MD, USA; 2Univ. of Alabama at Birmingham, USA; and 3NIAID, NIH, DHHS, Bethesda, MD, USA |
| 582 | Quality Assurance of Generic Antiretroviral Formulations in India G Ramachandran*1, E S Perloff2, L L von Moltke2, S Swaminathan1, and D J Greenblatt2 1Tuberculosis Res. Ctr., Indian Council of Med. Res., Chennai, India and 2Tufts Univ. Sch. of Med., Boston, MA, USA |
| 583 | Generic AZT vs d4T In HIV/TB Co-infection in Clinical Practice In India: An Observational Study D Saple*1, and S Vaidya2 1Grant Med. Coll. & G T Hosp., Mumbai, India and 2K J Somaiya Hosp. and Res. Ctr., Mumbai, India |
| 584 | Nevirapine- vs Efavirenz-based Antiretroviral Treatment in Naive Indian patients: Comparision of Effectiveness in a Clinical Cohort A K Patel*1, S Pujari2, K K Patel1, J K Patel3, N Shah1, B Patel4, and N Gupte5 1Sterling Hosp., Ahmedabad, India; 2Ruby Hall Clin., Pune, India; 3Adit Diagnostic and Molecular Biology Ctr., Ahmedabad, India; 4Shashwat Microbiology, Ahmedabad, India; and 5Consultant Biostatistician, Pune, India |
| 585 | Botswana/Baylor Antiretroviral Assessment Trial Experience with Antiretroviral Medications in a Resource Constrained Setting H Schwarzwald*1, G Anabwani2,3, D Bowman1, N Calles1, S Cron1, D Evans1, M Ferris1, H Jibril3, C Kozinetz1, K Mathuba3, S Mothobogwa3, O Tshume3, O Yarosh3, X Zhu1, and M Kline1 1Baylor Coll. of Med., Houston, TX, USA; 2Baylor Coll. of Med., Gaborone, Botswana; and 3Botswana-Baylor Children's Clin. Ctr. of Excellence, Gaborone |
| 586 | Weight and Body Shape Changes Associated with Antiretroviral Therapy in South India: Initial Prospective Analysis S Saghayam*1, N Kumarasamy1, S Solomon1, J Anitha1, S Chaguturu2, K Mayer2, T Flanigan2, and C Wanke3 1YRG Ctr. for AIDS Res. and Education, Chennai, India; 2Miriam Hosp., Brown Univ., Providence, RI, USA; and 3Tufts Univ. Sch. of Med., Boston, MA, USA |
| 587 | Initiation of HAART in Advanced HIV-infected Patients with CD4 <50 Cells/mm3 in a Resource-limited Setting: Efficacy and Tolerability S Sungkanuparph*, A Vibhagool, S Kiertiburanakul, W Manosuthi, and W Kiatatchasai Ramathibodi Hosp., Mahidol Univ. Faculty of Med., Bangkok, Thailand |
| 588 | Virologic and Immunologic Response to Highly Active Antiretroviral Therapy among HIV-infected Children in Cote d'Ivoire F Diomande1, H Lago1, D Hanson2, C Phares*3, F Anthony4, C Maurice1, B Monga1,5, J Nkengasong1,5, M Laga1, E Bissagnéné6, T Ellerbrock7, and M Nolan1,5 1Project RETRO-CI, Abidjan, Ivory Coast; 2CDC, Atlanta, GA, USA; 3Univ. of California, Berkeley, USA; 4Univ. Hosp. of Yopougon, Abidjan, Ivory Coast; 5CDC, Atlanta, GA, USA; 6Drug Access Initiative, Ministry of Hlth., Abidjan, Ivory Coast; and 7CDC, Global AIDS Prgm., Atlanta, GA, USA |
| 589 | Low-cost Strategies to Monitor Highly Active Antiretroviral Therapy in Resource-limited Settings N Kumarasamy*1, S K Chaguturu2, P Balakrishnan1, K H Mayer2, S Solomon1, and T P Flanigan2 1YRG Ctr. for AIDS Res. and Education, Chennai, India and 2Miriam Hosp., Brown Med. Sch., Providence, RI, USA |
| 590 | Development of an Affordable HIV-1 Viral Load Assay for Reference Laboratories in a Resource Constraned Settings N Rekhviashvili*, G Stevens, and W Stevens Natl. Hlth. Lab. Svc. and the Univ. of the Witwatersrand, Johannesburg South Africa |
| 591 | Clinical Monitoring of Cotrimoxazole, Duovir, and Nevimmune (Generic HAART) among Men and Women with AIDS in Zimbabwe D Bhattacharaya1,2, G Kadzirange*1,2, L S Zijenah1, E Matsikire3, S Moyo3,4, T Kufa3,4, O Tobaiwa3, M Chirenje1,2, C Maponga1, R Machekano1,5, D A Katzenstein2, and Zimbabwe AIDS Prevention Project 1Univ. of Zimbabwe, Harare; 2Stanford Univ., CA, USA; 3Zimbabwe AIDS Prevention Project, Harare; 4Medicin Sans Frontier, Harare, Zimbabwe; and 5San Mateo County AIDS Prgm., CA, USA |
| 592 | CD4 Response to HAART in Previously Untreated Adults with HIV Infection in Africa: The DART Trial P Munderi*1, C Kityo Mutuluuza2, A Reid3, and A S Walker4 1MRC/UVRI Prgm. on AIDS, Entebbe, Uganda; 2Joint Clin. Res. Ctr., Kampala, Uganda; 3Univ. of Zimbabwe, Harare; and 4MRC Clin. Trials Unit, London, UK |
| 593 | Persistence of X4-tropic Virus Despite Antiretroviral Treatment in Subtype C HIV E Johnston*1, M Ketunuti1, R Kantor1, D Bhattacharaya1, L Zijenah2, and D Katzenstein1 1Stanford Univ., CA, USA and 2Univ. of Zimbabwe, Harare |
| 594 | Mortality Is the Leading Cause of Loss to Follow-up among Antiretroviral Patients in Malawi M Hosseinipour*1, F Neuhann2, C Kanyama1, D Namarika3, and S Phiri2 1Univ. of North Carolina Project, Lilongwe Malawi; 2Lighthouse Clin., Lilongwe, Malawi; and 3Lilongwe Central Hosp., Malawi |
| 595 | A National Cohort Model for Assessing the Effect of an Expanded Access Program to Antiretroviral Therapy and the Short-term Predictors for Efficacy in a Middle-income Country C Beltrán*, M Wolff, R Morales, and C Chahín for the Chilean AIDS Cohort and CONASIDA, Chile |
| 596 | Challenges to Antiretroviral Drug Therapy in Resource-limited Settings: The Nigerian Experience E Ekong*1, V Idemyor2, O Akinlade3, and A Uwah4 1Nigeria HIV/AIDS Res. Network, Lagos; 2Advocate Bethany Hosp., Chicago, IL, USA; 3Military Hosp., Ikoyi, Lagos, Nigeria; and 4Central Publ. Lab., Yaba, Lagos, Nigeria |
